How Clinical Trials Work: Step-by-Step Process (2026 Guide)

Introduction

Every medicine you take every vaccine, every cancer therapy, every life-saving drug reached patients only after passing through a rigorous, multi-year clinical trial process. Clinical trials are the gold standard for generating evidence about a treatment’s safety and efficacy in humans. Yet despite their central role in modern medicine, the clinical trial process remains poorly understood outside specialist circles.

In 2026, clinical trials are faster, more inclusive, and more technologically sophisticated than ever before. Artificial intelligence, decentralised trial designs, wearable biosensors, and real-world evidence are transforming how trials are designed, conducted, and analysed. This guide walks you through the complete clinical trial process from the laboratory bench to regulatory approval with practical insights for sponsors, researchers, and healthcare professionals.

Why Are Clinical Trials Important?

Clinical trials are the only scientifically valid way to determine whether a new treatment works and is safe for human use. Without clinical trial evidence:

• Ineffective or harmful treatments could reach patients
• Regulatory agencies would have no basis for approval decisions
• Physicians would have no evidence to guide prescribing
• Drug development would remain based on anecdote rather than data

According to ClinicalTrials.gov, over 450,000 clinical studies are registered globally as of 2026, reflecting the scale of evidence generation underway across all therapeutic areas.

Drug Development Timeline: From Discovery to Approval

STEP 1 – Drug Discovery and Research

Identifying the Target and Lead Compound

Drug development begins with the identification of a biological target typically a protein, enzyme, or receptor implicated in a disease pathway. High-throughput screening (HTS) technologies test thousands to millions of chemical compounds against the target to identify promising ‘hits.’ Lead optimisation then refines chemical structures to maximise efficacy and minimise toxicity before advancing to preclinical studies.

STEP 2 – Preclinical Studies 

Before any human exposure, candidate compounds undergo extensive preclinical testing to establish a preliminary safety and pharmacological profile. Preclinical studies include:

• In vitro studies: cell culture models to assess mechanism of action and cytotoxicity
• In vivo studies: animal models to evaluate pharmacokinetics (PK), pharmacodynamics (PD), and toxicology
• Genotoxicity, carcinogenicity, and reproductive toxicity assessments
• Formulation development and stability studies

A successful preclinical package supports the Investigational New Drug (IND) application to the FDA, or the equivalent CTA (Clinical Trial Authorisation) to EMA/CDSCO.

STEP 3 – Protocol Development

The clinical trial protocol is the master document that defines every aspect of how the trial will be conducted. A well-written protocol aligned with ICH E6(R3) and regulatory expectations is critical to trial success. Key protocol elements include:

• Study objectives and endpoints (primary, secondary, exploratory)
• Study design (randomised, blinded, controlled, adaptive)
• Inclusion and exclusion criteria for patient eligibility
• Dosing regimen, route of administration, and treatment duration
• Safety monitoring plan including adverse event reporting procedures
• Statistical methodology and sample size justification

Biosphere CRO’s medical writing and clinical operations teams collaborate closely on protocol development to ensure scientific rigour, regulatory compliance, and operational feasibility. Visit biospherecro.com/medical-writing/

STEP 4 – Regulatory Submission (IND / CTA / CDSCO)

Before recruiting the first patient, sponsors must obtain regulatory authorisation to conduct human trials.

Regulatory submissions vary by jurisdiction:

Biosphere CRO’s regulatory affairs team manages submissions across all major jurisdictions, ensuring complete, compliant dossiers that minimise review timelines. biospherecro.com/regulatory-affairs/

STEP 5 – Ethics Committee Approval 

All clinical trials must be reviewed and approved by an Independent Ethics Committee (IEC) or Institutional Review Board (IRB) to protect patient rights, safety, and welfare. Ethics committee review covers:

• Scientific validity of the trial protocol
• Risk-benefit assessment for participants
• Informed consent process and documentation
• Patient information sheets in appropriate local languages
• Compensation and insurance arrangements for trial participants

STEP 6 – Site Selection and Qualification

Selecting appropriate investigator sites is one of the most critical determinants of trial success. Poor site selection is a leading cause of enrolment delays. Site qualification activities include feasibility assessments, investigator CVs and GCP certification review, site infrastructure evaluation, and patient population assessment. Biosphere CRO maintains an established network of qualified investigator sites across India, enabling rapid site activation.

STEP 7 – Patient Recruitment

Patient recruitment accounts for approximately 30-40% of total trial timelines in most studies. Modern CROs deploy multiple recruitment strategies:

• Digital recruitment: social media, patient advocacy networks, condition-specific platforms
• EHR mining using AI to identify eligible patients across hospital systems
• Decentralised trial options expanding geographic reach beyond traditional site catchment areas
• Patient-centric screening – simplified eligibility criteria and remote pre-screening
• Diversity and inclusion initiatives ensuring representative trial populations

STEP 8 – Clinical Trial Phases (I through IV)

Clinical trials follow a structured phased development programme:

Phase I — Safety and Dosing

First-in-human studies conducted in 20-80 healthy volunteers (or patients for oncology). Objectives: establish maximum tolerated dose (MTD), characterise pharmacokinetics, and identify dose-limiting toxicities. Duration: 1-2 years.

Phase II — Proof of Concept

Expanded studies in 100-300 patients with the target disease. Objectives: preliminary evidence of efficacy, further safety characterisation, dose selection for Phase III. Duration: 2-3 years.

Phase III — Pivotal Confirmatory Trials

Large-scale, randomised controlled trials (RCTs) in 1,000-5,000+ patients across multiple sites globally. Objectives: confirm efficacy vs. standard of care or placebo, characterise safety profile comprehensively, support regulatory approval. Duration: 3-5 years.

Phase IV — Post-Marketing Surveillance

Ongoing safety monitoring after regulatory approval in the general patient population. Objectives: detect rare adverse events, evaluate long-term safety, support label expansions. Duration: ongoing.

STEP 9 – Clinical Operations

Day-to-day trial conduct is managed by clinical operations professionals throughout the trial period. Key clinical operations activities include investigator site monitoring (on-site and remote), protocol compliance oversight, adverse event reporting, query management, and supply chain management for investigational medicinal products (IMP). biospherecro.com/clinical-operation/

STEP 10 – Remote Monitoring Services

Risk-based remote monitoring (RBM) allows CRAs to review 100% of incoming data centrally, identify statistical outliers and data anomalies in real time, and prioritise on-site visits to sites with demonstrated risk signals – significantly reducing monitoring costs without compromising data integrity.

STEP 11 — Data Management

CRF Designing

A Case Report Form (CRF) is the primary data collection tool in clinical trials. Well-designed paper or electronic CRFs capture all required data points efficiently, minimising transcription errors and query volumes.

eCRF Designing

Electronic CRFs (eCRFs) are deployed within EDC platforms (Medidata Rave, Oracle Inform, REDCap). eCRFs incorporate real-time validation checks, mandatory field controls, and direct data entry by site staff – enabling immediate data availability and central monitoring.

Clinical Database Design

The clinical database is built to CDISC standards (CDASH for data collection, SDTM for submission datasets) ensuring regulatory acceptability by FDA and EMA. Database validation documents (DVP/UAT) verify that all specifications are correctly implemented prior to first patient enrolment.

Biosphere CRO’s data management team delivers end-to-end data management services from eCRF design through database lock, fully aligned with CDISC and ICH E9 standards. biospherecro.com/data-management/

STEP 12 – Statistical Analysis 

Biostatistical analysis transforms raw trial data into regulatory-grade evidence. Key statistical activities include:

• Statistical Analysis Plan (SAP) development prior to database lock
• Randomisation schedules and blinding maintenance
• Interim analyses for adaptive trial designs and Data Safety Monitoring Boards (DSMB)
• Primary and secondary endpoint analysis using pre-specified methods
• Integrated summaries of safety (ISS) and efficacy (ISE) for regulatory dossiers

Biosphere CRO’s biostatistics team works in SAS and R, delivering analyses to FDA/EMA standards with full audit trails. biospherecro.com/statistical-analysis/

STEP 13 – Medical Writing 

Regulatory medical writing translates clinical and statistical results into structured regulatory documents. Key deliverables include:

• Clinical Study Report (CSR) – the primary summary of trial results per ICH E3
• Integrated Summaries of Safety and Efficacy (ISS/ISE)
• Common Technical Document (CTD) modules for NDA/BLA/MAA submissions
• Investigator’s Brochure (IB) updates throughout the trial
• Patient narratives for serious adverse events
• Publications and conference abstracts

STEP 14 – Regulatory Submission and Approval

Following completion of pivotal Phase III trials, sponsors compile a comprehensive regulatory dossier

New Drug Application (NDA) in the USA, Marketing Authorisation Application (MAA) in Europe, or New Drug Submission to CDSCO in India. The dossier is structured in Common Technical Document (CTD) format accepted by all ICH member authorities. FDA review timelines average 10-12 months for standard review and 6 months for priority review. CDSCO approval timelines have improved significantly following the New Drugs Rules 2019.

AI and Technology Reshaping Clinical Trials in 2026

Common Challenges in Clinical Trials and Practical Solutions

Partner with Biosphere CRO for End-to-End Clinical Trial Services

Biosphere CRO delivers the expertise, technology, and global reach to support your clinical trial from first concept to regulatory approval. Whether you need full-service trial management or specific functional support, our team is ready to partner with you.

® Clinical Trial Services: biospherecro.com

® Clinical Operations: biospherecro.com/clinical-operation/

® Medical Writing: biospherecro.com/medical-writing/

® Regulatory Affairs: biospherecro.com/regulatory-affairs/

® Data Management: biospherecro.com/data-management/

® Biostatistics: biospherecro.com/statistical-analysis/

Contact Biosphere CRO today – your trusted global clinical research partner.

— Biosphere CRO | Advancing Science. Accelerating Approvals.